In today’s high-stakes biotech environment, the difference between success and failure often lies in early strategic decisions leading up to IND submission and into First-in-Human trials. With constrained capital and sharpened investor expectations, companies must align science, strategy, and investment readiness from the very start.
This webinar presented by Certara in partnership with Fierce Biotech explores how forward-thinking biotech leaders are integrating early development strategies, asset evaluation, and venture planning sooner to build stronger, model-informed programs, attract funding, and accelerate outcomes while managing risk.
Through real-world examples and expert insight, we’ll uncover the early development choices that determine long-term outcomes, and how a strategic, data-first approach helps biotech innovators bring the right drug to the right patient, faster.
Key Learning Objectives:
The goal and objective are for participants to:
- Identify the most common strategic pitfalls that lead to early-stage failure and how to avoid them
- Understand how early, integrated decision-making improves development outcomes and investor confidence
- Learn best practices for evaluating therapeutic potential and program risk with clarity and confidence
- See how early strategic planning connects science, funding, and commercialization for lasting success
Speakers
- G Mikael Dolsten MD, PhD, Founding CEO & Chairman Quarry Thera
- Paula Kaplan-Lefko, PhD, Director of Regulatory Strategy Atara Biotherapeutics
- Fran Brown, PhD, Senior Vice President & Head of Drug Development Science Certara Drug Development Solutions
- Max Vargas, PhD, MBA, Vice President, Evidence & Access Strategy Certara Drug Development Solutions
